[The combined action of 2,5,6-H3-DOPA and alkylating agents on Harding-Passy melanoma].
D000818:Animals; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use*; D008545:Melanoma / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008558:Melphalan / Q000627:therapeutic use*; D051379:Mice; D008807:Mice, Inbred BALB C; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000532:radiotherapy; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D013997:Time Factors; D014316:Tritium / Q000627:therapeutic use*
D011838:Radiation-Sensitizing Agents; D014316:Tritium; D004295:Dihydroxyphenylalanine; D003520:Cyclophosphamide; D008558:Melphalan
O kombinirovannom vozdeĭstvii DOFA-2,5,6-H3 i alkiliruiushchikh agentov na mealnomu Garding-Passi.